HONG KONG – Following a priority review, Astrazeneca plc won approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Tagrisso (osimertinib). The drug is now greenlighted as a first-line treatment in patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).